W. Rowlands
Director/Board Member chez A-LABS CAPITAL II CORP.
Profil
W.
Bruce Rowlands is an Independent Director at A-Labs Capital II Corp.
He was the Chairman of XORTX Therapeutics, Inc. from 2018 to 2021.
He was a Director at Talisker Resources Ltd.
in 2018.
He also served as a Director at XORTX Pharma Corp.
He was a Director & Vice President at Dominick & Dominick Securities, Inc. from 1999 to 2003.
He was the Senior Vice President-Planning & Public Affairs at Aptose Biosciences, Inc. from 2003 to 2005.
Currently, he holds the position of Independent Director at A-Labs Capital II Corp.
Postes actifs de W. Rowlands
| Sociétés | Poste | Début |
|---|---|---|
| A-LABS CAPITAL II CORP. | Director/Board Member | 05/09/2018 |
Anciens postes connus de W. Rowlands
| Sociétés | Poste | Fin |
|---|---|---|
| XORTX THERAPEUTICS INC. | Chairman | 20/12/2021 |
| TALISKER RESOURCES LTD. | Chief Executive Officer | 15/03/2018 |
| APTOSE BIOSCIENCES INC. | Public Communications Contact | 01/01/2005 |
| Dominick & Dominick Securities, Inc. | Director/Board Member | 01/01/2003 |
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| TALISKER RESOURCES LTD. | Non-Energy Minerals |
| XORTX THERAPEUTICS INC. | Health Technology |
| A-LABS CAPITAL II CORP. | Finance |
| Entreprise privées | 2 |
|---|---|
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Health Technology |
| Dominick & Dominick Securities, Inc. |
